Skip to content
10-K

Annual Report

Pear Therapeutics, Inc.

0001835567-22-000010

← back to feed
Filed
Mar 29, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2021 · Mar 21, 2022 137.84M sh
Long Term Debt FY 2021 · Dec 31, 2021 $0
Shares Diluted FY 2021 · Dec 31, 2020 89.22M sh
Capex FY 2021 · Dec 31, 2020 $3.9M
Operating Cash Flow FY 2021 · Dec 31, 2020 −$67.89M
Short Term Debt FY 2021 · Dec 31, 2020 $26.35M
Short Term Investments FY 2021 · Dec 31, 2020 $13.54M
Cash And Equivalents FY 2021 · Dec 31, 2020 $110.9M
Current Liabilities FY 2021 · Dec 31, 2020 $40.69M
Total Liabilities FY 2021 · Dec 31, 2020 $45.25M
Current Assets FY 2021 · Dec 31, 2020 $126.06M
Total Assets FY 2021 · Dec 31, 2020 $132.37M
Eps Diluted FY 2021 · Dec 31, 2020 −$1.21
Eps Basic FY 2021 · Dec 31, 2020 −$1.21
Sga Expense FY 2021 · Dec 31, 2020 $56.23M
Rd Expense FY 2021 · Dec 31, 2020 $28.08M
Net Income FY 2021 · Dec 31, 2020 −$97.02M
Operating Income FY 2021 · Dec 31, 2020 −$76.64M
Cost Of Revenue FY 2021 · Dec 31, 2020 $1.72M
Revenue FY 2021 · Dec 31, 2020 $9.38M
Stockholders Equity FY 2021 · Dec 31, 2019 −$66.04M